Tenalisib for metastatic triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a drug called Tenalisib in people with metastatic triple-negative breast cancer who have already tried 1 to 3 chemotherapy treatments. It aims to see if Tenalisib can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with triple-negative breast cancer (confirmed by biopsy).
- You have metastatic breast cancer (cancer that has spread to other parts of the body).
- You have had 1 to 3 prior chemotherapy treatments for metastatic cancer.
- You have at least one tumor that can be measured on scans (tumors only in the bones do not count).
- You are up and about for at least half of your waking hours (ECOG performance status 0 to 2).
- You have adequate liver, kidney, and blood cell function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called QLC5513, either by itself or combined with another drug (QL1706), for people with triple-negative breast cancer that has continued to grow despite prior treatment. The goal is to see if this new approach can shrink tumors or slow the cancer's progression, and it might be an option if standard treatments have stopped working.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
This trial tests a new pill, Zn-Telomir, for people with advanced triple-negative breast cancer that has spread or cannot be removed by surgery and has gotten worse after previous treatments. The goal is to see if this drug can shrink tumors or slow the cancer.
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
Hear when a new Triple Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.